Oncos
Therapeutics introduced the effective initiation of its Phase I clinical study
of CGTG-102, an oncolytic adenovirus advised being a potentially new therapy
for a lot of types of solid tumors. The initial affected individuals have
completed the safety assessment section of the study.
"We
are precisely proud to become the first clinic in Northern Europe to start a
clinical study by using oncolytic viruses," comments the Principal
Investigator of a typical study, Chief Physician of Docrates Hospital, Dr. Timo
Joensuu. "We perceive that in fact oncolytic adenoviruses, a generally
appropriately tolerated therapy, can have a necessary function in the future of
cancer therapies."
The
individual data grabbed in the last 5 years have contributed substantially into
the design of the complete clinical development program of a typical company.
"Together with existing clinical security files, and that is unique to
this particular phase of development, we also have a wealth of supportive data
to steer the choice of target tumor types, optimal therapy administration, as
well as other essential factors such as clues regarding mechanism of act and
possible biomarkers. We are incredibly excited about the look of our entire
invention program driven by clinical data," summarizes Chief Medicinal
Official and Head of Research of Oncos Therapeutics, Mikael von Euler.
No comments:
Post a Comment